This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The basis for the analysis of the clinical study (intention to treat or completers only) was not clearly stated. The primary health outcomes studied included survival rate and revision rate. Groups were not compared in terms of demographic characteristics.
Effectiveness results
During the years [1987] [1988] [1989] [1990] [1991] [1992] [1993] 199 combinations of cemented and uncemented prostheses were used. Uncemented arthroplasties were most commonly used in younger patients and the pre-operative diagnosis was less often primary coxarthrosis. The probability of revision at 5 years was 4.4% in the group of all other primary THR, compared to 2.2% in the reference group. The revision rates were as follows:
at 5 years for the Ti-Fit/Bio-Fit combination, 26%, at 4 years for the Coxa/Femora combination, 17%, at 5 years for THR with low-viscosity cement, 7%, and at 3 years for the Boneloc combination, 8%.
Clinical conclusions
The revision rate was lowest in the reference group.
Modelling
No modelling was undertaken.
Measure of benefits used in the economic analysis
The number of revisions was used as the primary measure of benefits.
Direct costs
Direct costs were discounted at an annual rate of 3%. Quantities and costs were reported separately. Direct costs included the cost of the intervention and the treatment of post-operative complications. The quantity/cost boundary adopted was that of the hospital. The estimation of quantities and costs was based on actual data. Data were collected from the Norwegian Arthroplasty Register. The price year was 1994.
Statistical analysis of costs
Not reported.
Indirect Costs
Not included.
Currency
Norwegian kroner (NOK) with US$1 = 6.5 NOK.
Sensitivity analysis
